Atlas Trials

Graft-versus-host-disease (GVHD)

23 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Graft-versus-host-disease (GVHD)

RecordFirmDate
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (NCT04167514)CSL Behring2020-01-09
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids (NCT03616184)University of Nebraska2018-09-05
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (NCT03139604)Incyte Corporation2017-07-19
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (NCT03112603)Incyte Corporation2017-06-29
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) (NCT02953678)Incyte Corporation2016-12-30
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD (NCT02614612)Incyte Corporation2015-12-01
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major (NCT02342145)Zhongming Zhang2015-04-01
Maraviroc as GVHD Prophylaxis in Transplant Recipients (NCT02167451)Children's Hospital Medical Center, Cincinnati2014-07-01
CliniMACS® CD34+ Reagent System for Expanded Access Use (NCT02026934)Joseph Antin2013-03-01
University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol (NCT01463475)University of Wisconsin, Madison2011-09-01
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis (NCT01324908)Vanderbilt-Ingram Cancer Center2011-07-01
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD (NCT05722912)Incyte Corporation
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant (NCT03147742)Incyte Corporation

Track Graft-versus-host-disease (GVHD) automatically

Every clearance here is in the API, with alerts when new ones post.